Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
Robert Hsu(University of Southern California), Jorge J. Nieva(University of Southern California), Denaly Chen(University of Southern California), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Wendy Cozen(University of Southern California), Alexander I. Spira(Virginia Cancer Specialists), Misako Nagasaka(University of California, Irvine), Gilberto Lopes(University of Miami), Mark A. Socinski(Florida Hospital Cancer Institute), Bing Xia(Rutgers, The State University of New Jersey), Chul Kim(Georgetown University), Hossein Borghaei(Fox Chase Cancer Center), Antoinette J. Wozniak(Wayne State University), Luis E. Raez(Florida International University)
Cited by 4
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k